Prestige Biopharma announced on the 26th that it has signed a sales and supply agreement for the biosimilar 'Tuznue' (ingredient name trastuzumab) with Teva Pharmaceutical Industries' subsidiary, Teva Pharmaceutical International GmbH.
Tuznue is a biosimilar of the breast cancer and stomach cancer treatment Herceptin (ingredient name trastuzumab). Prestige Biopharma received sales approval for Tuznue from the European Commission (EC) last September and will start supplying it to 31 markets in Europe, including the United Kingdom, Germany, and France.
Under this agreement, Teva has secured the marketing and distribution rights for Tuznue in Europe. Prestige Biopharma's contract development and manufacturing organization (CDMO) subsidiary, Prestige Biologics, will be responsible for production and supply at facilities certified for Good Manufacturing Practice (GMP) by the European Union (EU).
Park So-yeon, chairperson of Prestige Biopharma Group, said, "It is a significant achievement to be able to provide Tuznue to patients across Europe through collaboration with a leading global biopharmaceutical company like Teva," and noted, "Based on Teva's market accessibility, the success of Tuznue will not only be ensured, but we will also accelerate the development of our 14 biosimilar pipeline, including the Avastin biosimilar (bevacizumab)."